Ended the year with strong cash position of $59.2 million Revenues grew 81% year-over-year to $0.5 million for Q4 2021 Revenues grew 72% year-over-year to $1.5 million for FY 2021 Gross profit of $31,818 for Q4 2021 Completed the acquisition of the Neurology Centre of Toronto in September 2021 Two clinical trials about to launch: Phase 1 study for proprietary psilocybe extract and Phase 3 open…

Source

Previous articleMydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Next articleAlgernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2